Kymera Therapeutics, Inc.
KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$64.94
Price+2.06%
$1.31
1Y
Price
Market Cap
$4.672b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-736.8%
EBITDA Margin-667.6%
Net Profit Margin-527.9%
Free Cash Flow MarginRevenue
$44.711m
-5.0%
1y CAGR+7.6%
3y CAGR-3.2%
5y CAGREarnings
-$275.434m
-23.0%
1y CAGR-24.0%
3y CAGR-31.8%
5y CAGREPS
-$3.47
-16.4%
1y CAGR-8.0%
3y CAGR-15.6%
5y CAGRBook Value
$971.480m
$1.131b
Assets$159.588m
Liabilities$85.714m
DebtDebt to Assets
7.6%
-0.3x
Debt to EBITDAFree Cash Flow
-$252.917m
-22.0%
1y CAGR-20.3%
3y CAGR-20.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company